07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

BCR/ABL1 Quant Test regulatory update

Asuragen received CE Mark approval in Europe for its BCR/ABL1 Quant Test to aid in the assessment of complete cytogenetic response (CCyR), major molecular response (MMR), minimal residual disease and relapse in Philadelphia chromosome-positive chronic...